SCHEMBL1498503

SCHEMBL1498503

O=C(Nc1ccc(N2CCN(C(=O)OCc3ccccc3)CC2)c(F)c1)OCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.53
NPC1 O15118 3/20 0.53
ALDH1A1 P00352 2/20 0.53
TSHR P16473 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
GRM5 P41594 1/20 0.53
LMNA P02545 1/20 0.53
HPGD P15428 1/20 0.53
ALOX15 P16050 1/20 0.53
MAPK1 P28482 1/20 0.53
HSD17B10 Q99714 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.51
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TP53 P04637 1/20 0.49
ATM Q13315 1/20 0.49
NPY2R P49146 2/20 0.48
CYP2C9 P11712 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6509573 0.93 GRM5 (0.53) MAPTNPC1ALDH1A1TSHRNPSR1
SCHEMBL6510132 0.91 NPY2R (0.52) MAPTNPC1ALDH1A1TSHRNPSR1
SCHEMBL2087624 0.91 TMEM97 (0.49) MAPTNPC1ALDH1A1TSHRNPSR1
SCHEMBL1955176 0.89 MAPT (0.62) MAPTNPC1ALDH1A1TSHRGRM5
SCHEMBL14898019 0.88 MAPT (0.54) MAPTNPC1ALDH1A1TSHRGRM5
SCHEMBL14168649 0.88 TP53 (0.47) MAPTNPC1ALDH1A1TSHRGRM5
SCHEMBL26771614 0.87 NPY2R (0.49) MAPTNPC1ALDH1A1TSHRNPSR1
SCHEMBL6465956 0.87 NPY2R (0.54) MAPTNPC1ALDH1A1TSHRLMNA
SCHEMBL7830623 0.87 TGM2 (0.49) MAPTNPC1ALDH1A1TSHRGRM5
SCHEMBL30771563 0.86 NPC1 (0.61) MAPTNPC1ALDH1A1TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124597-A1 BORON CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2011-05-26 US disclosed
WO-2011037731-A1 BORON CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2011-03-31 WO disclosed
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-20080146573-A1 PREPARATION AND UTILITY OF SUBSTITUTED OXZOLIDINONES AUSPEX PHARMACEUTICALS, INC. (US) 2008-06-19 US disclosed
WO-2008070619-A1 DEUTERATED OXAZOLIDINONES AND THEIR USE AS ANTIBIOTICS AUSPEX PHARMACEUTICALS, INC. (US) 2008-06-12 WO disclosed
WO-2007138381-A2 PHOSPHONATED OXAZOLIDINONES AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS TARGANTA THERAPEUTICS INC. (CA) 2007-12-06 WO disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed
US-7141588-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER, INC. (US) 2006-11-28 US disclosed
EP-1478629-B1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN CO LLC (US) 2006-10-11 EP disclosed
US-7049443-B2 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound PHARMACIA & UPJOHN COMPANY (US) 2006-05-23 US disclosed
EP-1451164-A2 AMIDE DERIVATIVES HAVING IMPROVED SOLUBILITY PHARMACIA & UPJOHN COMPANY (US) 2004-09-01 EP disclosed
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US disclosed
US-20040143131-A1 in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates PHARMACIA & UPJOHN COMPANY 2004-07-22 US disclosed
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-03-04 US disclosed
US-20040014967-A1 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound PHARMACIA & UPJOHN COMPANY 2004-01-22 US disclosed
WO-2003072553-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2003-09-04 WO disclosed
EP-1328509-A1 METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS Pharmacia & Upjohn Company (US) 2003-07-23 EP disclosed
WO-2003006440-A2 AMIDE-CONTAINING COMPOUND HAVING IMPROVED SOLUBILITY AND METHOD OF IMPROVING THE SOLUBILITY OF AN AMIDE-CONTAINING COMPOUND PHARMACIA & UPJOHN COMPANY (US) 2003-01-23 WO disclosed
US-20020086900-A1 Methods of producing oxazolidinone compounds PERRAULT WILLIAM R (US) 2002-07-04 US disclosed
WO-2002032857-A1 METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124597-A1 BORON CONTAINING SMALL MOLECULES BCL6B, BCL6, BLVRB MAPT 1995/4885NPC1 537/4885ALDH1A1 4730/4885
US-20040143131-A1 in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates TET1, NAT10, TET3 MAPT 2954/4885NPC1 3567/4885ALDH1A1 1487/4885
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAPT 4491/4885NPC1 2741/4885ALDH1A1 956/4885
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAPT 4491/4885NPC1 2741/4885ALDH1A1 956/4885
US-20020086900-A1 Methods of producing oxazolidinone compounds TET3, TET1, AZI2 MAPT 3115/4885NPC1 3328/4885ALDH1A1 1609/4885
US-20040014967-A1 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound AADAC, AAAS, SLC7A1 MAPT 1484/4885NPC1 500/4885ALDH1A1 1622/4885
US-20080146573-A1 PREPARATION AND UTILITY OF SUBSTITUTED OXZOLIDINONES OXA1L, CYP2C19, CYP2C9 MAPT 3930/4885NPC1 3244/4885ALDH1A1 328/4885
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAPT 4491/4885NPC1 2741/4885ALDH1A1 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.